The common theme of departmental research programs is molecular medicine: that is, the elucidation of the pathogenesis of disease at the molecular level and the application of this knowledge to the design and implementation of novel therapies. Our established programs include cancer biology, vascular biology, genetics, molecular hemostasis, amyloidogenesis and cholesterol metabolism. Through collaborations with the Queen’s Cancer Research Institute we also have an emerging strength in translational research.
Researchers with Labs
- David Berman, MD, PhD Biomarkers and therapeutic targets for bladder and prostate cancer
- Tricia Cottrell, MD, PhD https://www.cottrelllab.org/ The cutting edge of immunotherapy biomarker research
- Scott Davey, PhD Basic and translational studies of the DNA damage response
- Peter Greer, PhD Identification and validation of novel therapeutic targets in breast cancer
- Harriet Feilotter, PhD, FCCMG Biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer
- Paula James, MD Molecular hemostasis
- David Lillicrap, MD Molecular hemostasis
- Lois Mulligan, PhD Role of the RET proto-oncogene in cancer
- Christopher Nicol, PhD Cell specific roles of PPARs in breast cancer
- Anna Panchenko, PhD Molecular mechanisms of cancer: detecting drivers with computational and hybrid approaches
- Michael Rauh, MD, PhD Translational studies in myeloid blood cancers and innate immune tolerance
- Neil Renwick, MD, PhD Translational RNA Biology
- Xiaolong Yang, PhD The molecular and cellular function of tumor suppressors in human cancer
Page Last Updated: 2024 October 21